Effects of dapagliflozin on renal function in type 1 diabetes patients in the real world: A retrospective multicenter study of the KAMOGAWA-A cohort
- 17 June 2023
- journal article
- research article
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 202, 110794
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Sodium–glucose cotransporter 2 inhibitors reduce day‐to‐day glucose variability in patients with type 1 diabetesJournal of Diabetes Investigation, 2020
- Use of Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic KetoacidosisDiabetes Care, 2019
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2019
- SGLT inhibitor adjunct therapy in type 1 diabetesDiabetologia, 2018
- Empagliflozin and Progression of Kidney Disease in Type 2 DiabetesNew England Journal of Medicine, 2016
- Estimated Life Expectancy in a Scottish Cohort With Type 1 Diabetes, 2008-2010JAMA, 2015
- Decline in Estimated Glomerular Filtration Rate and Subsequent Risk of End-Stage Renal Disease and MortalityJAMA, 2014
- The early decline in renal function in patients with type 1 diabetes and proteinuria predicts the risk of end-stage renal diseaseKidney International, 2012
- The changing epidemiology of type 1 diabetes: why is it going through the roof?Diabetes/Metabolism Research and Reviews, 2010
- Revised Equations for Estimated GFR From Serum Creatinine in JapanAmerican Journal of Kidney Diseases, 2009